Bremelanotide (PT-141)
Bremelanotide, also called PT-141 (Vyleesi): the approved use, side effects, who should not take it, and how it differs from Melanotan II.
FDA-approved, narrow use · Evidence grade B · Reviewed
Bremelanotide (PT-141) (Vyleesi). Melanocortin receptor agonist.
BFDA-approved, narrow use. Evidence grade B: human trials, narrow or pending approval.
What is Bremelanotide (PT-141)?
Bremelanotide activates melanocortin receptors. How that improves sexual desire is not fully understood.
Is Bremelanotide (PT-141) FDA-approved?
Approved in June 2019 as Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is not approved for men.
What does the evidence show for Bremelanotide (PT-141)?
Two 24-week placebo-controlled trials in about 1,250 women. Benefits were modest.
What are the known risks of Bremelanotide (PT-141)?
Nausea affected about 40% of trial participants. Flushing, injection-site reactions and headache were also common. Blood pressure rises for a time after each dose, so it is not for people with uncontrolled high blood pressure or known cardiovascular disease. Darkening of the skin or gums can occur.
How is Bremelanotide (PT-141) measured?
The approved product is a single-dose autoinjector, so there is nothing to calculate.
Sources: FDA: Vyleesi drug trials snapshot; Contemporary OB/GYN: bremelanotide approval. This profile does not recommend any dose or use.
For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.